1 min read
Add as a preferred source on GoogleCentury Therapeutics Posts $0.11 Q3 Loss Per Share as Net Loss Narrows
The company had $174.1 million in cash, cash equivalents and investments at quarter-end and estimated the balance would support operations into the first quarter of 2029.
Century Therapeutics, Inc. recorded a GAAP loss of $0.11 per share for the third quarter ended Sept. 30, 2026, while its net loss narrowed from a year earlier.
Century’s net loss was $23.5 million, compared with $34.4 million in the same quarter a year earlier.
Cash, cash equivalents and investments totaled $174.1 million at quarter-end. Century estimated that balance would support operations into the first quarter of 2029.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.